Get the Stockscreener App
4.42
9.05%
-0.44
After Hours:
3.44
-0.98
-22.17%
Design Therapeutics Inc Stock (DSGN) Latest News
Design Therapeutics, Inc. (NASDAQ:DSGN) Short Interest Update - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Position Increased by JPMorgan Chase & Co. - Defense World
Design Therapeutics: Not A Complete Washout Despite Setback - Seeking Alpha
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Breakthrough in Kidney Disease Treatment: Regulus Drug Shows Promising Results in Clinical Trial - StockTitan
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases - Yahoo Finance
Assenagon Asset Management S.A. Trims Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Ovid Therapeutics Inc. (NASDAQ:OVID) Position Cut by Assenagon Asset Management S.A. - Defense World
Assenagon Asset Management S.A. Buys New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Lululemon Athletica Inc. (NASDAQ:LULU) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Assenagon Asset Management S.A. Sells 782 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
Spinocerebellar Ataxias Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart
Long Term Trading Analysis for (DSGN) - Stock Traders Daily
3 Promising US Penny Stocks With Market Caps Under $900M - Simply Wall St
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Design Therapeutics, Inc. (NASDAQ:DSGN) Sees Significant Increase in Short Interest - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Short Interest Up 8.1% in December - MarketBeat
Barclays PLC Purchases 24,602 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Sold by Jane Street Group LLC - Defense World
Design Therapeutics Updates Corporate Presentation for Investors - TipRanks
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE - BioSpace
Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases - Yahoo Finance
Dyno Therapeutics Announces Exercise of Option by Roche for Next-Generation AAV Vector for Neurological Gene Therapy - Business Wire
4D Molecular, FDA agree on phase 3 design for DME candidate - Seeking Alpha
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery - Yahoo Finance
Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics - Business Wire
Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome - BioSpace
Barclays PLC Grows Position in Hooker Furnishings Co. (NASDAQ:HOFT) - Defense World
Geode Capital Management LLC Grows Stock Holdings in BARK, Inc. (NYSE:BARK) - Defense World
Geode Capital Management LLC Has $4.22 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Geode Capital Management LLC Buys 50,579 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
LPOXY Therapeutics Acquires Assets from Xeno Biosciences - Contract Pharma
Barclays PLC Has $520,000 Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics Inc (NASDAQ: DSGN) Could Fell Another -94.49% - Stocks Register
State Street Corp Has $3.72 Million Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
(DSGN) Trading Advice - Stock Traders Daily
Why Cemtrex Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket - Benzinga
PHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical Study - Business Wire
Toronto-Dominion Bank (NYSE:TD) Stock Rating Lowered by StockNews.com - Defense World
(DSGN) Investment Analysis - Stock Traders Daily
Design Therapeutics director Prasad Deepa sells shares worth $23,863 - Investing.com India
Design Therapeutics director Prasad Deepa sells shares worth $23,863 By Investing.com - Investing.com South Africa
Insider Selling: Design Therapeutics, Inc. (NASDAQ:DSGN) Director Sells 3,806 Shares of Stock - MarketBeat
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga
The Manufacturers Life Insurance Company Purchases Shares of 13,221 Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Accelerating the Design of Candidate Drugs Using Amazon SageMaker with Nimbus Therapeutics - AWS Blog
Design Therapeutics' SWOT analysis: geneTAC stock faces early-stage hurdles - Investing.com
Fmr LLC Has $4.46 Million Stake in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Neurological stocks rise and fall on clinical data; index down - BioWorld Online
Design Therapeutics Gains 11%, Insider Trades Reap Benefit - Simply Wall St
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC - PR Newswire
Design Therapeutics, Inc. (NASDAQ:DSGN) Position Boosted by Frazier Life Sciences Management L.P. - MarketBeat
Orion Corporation Enters Collaboration With Evariste to Design Inhibitors of an Undisclosed Target - Yahoo Finance
Jacobs Levy Equity Management Inc. Reduces Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - MarketBeat
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):